LivaNova/$LIVN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About LivaNova

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Ticker

$LIVN
Sector
Primary listing

Employees

2,900

LivaNova Metrics

BasicAdvanced
$2.8B
-
-$3.89
0.95
-

What the Analysts think about LivaNova

Analyst ratings (Buy, Hold, Sell) for LivaNova stock.

Bulls say / Bears say

LivaNova achieved strong organic revenue growth of 10.3% in Q2, surpassing consensus with $352.5 million, driven by 14.7% growth in the cardiopulmonary segment and 6.2% in neuromodulation (Investing.com, Nasdaq)
The company increased full-year 2025 revenue guidance by 200 basis points to 8.0%–9.0% on a constant-currency basis (9.0%–10.0% organic) and raised adjusted EPS guidance to $3.70–$3.80, highlighting strong execution and visibility (Nasdaq)
LivaNova began the CMS reconsideration process for national coverage of VNS Therapy™ in treatment-resistant depression, backed by five RECOVER study publications and 24-month CORE-VNS data confirming sustained benefits in drug-resistant epilepsy, paving the way for broader reimbursement (BusinessWire)
The cardiopulmonary segment is experiencing supply constraints with third-party oxygenators, which could prevent LivaNova from fully meeting demand for consumables and may limit future revenue growth (TipRanks )
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

LivaNova Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LivaNova Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LIVN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy LivaNova stock | $LIVN Share Price | Lightyear